SCHEMBL9106023

SCHEMBL9106023

CC(=O)Nc1cc(-c2nc(-c3cc(CN(C)C)ccc3Cl)c(-c3nnc[nH]3)o2)c(C)cn1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.35
PIK3C3 Q8NEB9 4/20 0.33
F10 P00742 1/20 0.33
KLKB1 P03952 1/20 0.33
MAPK14 Q16539 1/20 0.32
AGPAT2 O15120 1/20 0.31
DDR2 Q16832 1/20 0.31
SRC P12931 1/20 0.31
ABL1 P00519 1/20 0.31
LCK P06239 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9888752 0.87 USP2 (0.36) PIK3C3F10ABL1ALDH1A1HSP90AA1
SCHEMBL627198 0.86 PIK3C3 (0.39) PIK3C3MAPK14ABL1ALDH1A1
SCHEMBL9888610 0.85 S1PR4 (0.38) S1PR4PIK3C3F10KLKB1MAPK14
SCHEMBL626895 0.82 PIK3C3 (0.39) PIK3C3ABL1
SCHEMBL9890626 0.80 PIK3C3 (0.35) PIK3C3MAPK14ABL1
SCHEMBL9890040 0.78 WDR5 (0.36) F10ALDH1A1
SCHEMBL9890038 0.75 AGPAT2 (0.38) PIK3C3AGPAT2ABL1ALDH1A1
SCHEMBL627636 0.74 ABL1 (0.47) ABL1
SCHEMBL16167587 0.74 PIK3C3 (0.40) PIK3C3ABL1
SCHEMBL9888652 0.72 PIK3C3 (0.39) PIK3C3ABL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 S1PR4 1864/4885PIK3C3 52/4885F10 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.